Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
rs of the Perrigo Board of Directors. The Company stated that the appointment of the Company's Board follows the completion of its acquisition of Elan Corporation, plc, in a transaction valued at approximately $8.6 billion. The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Arena Pharmaceuticals, Inc. Research Report
On December 26, 2013, Arena Pharmaceuticals, Inc.'s (Arena Pharmaceuticals) stock went up by 6.03%, to close at $5.98. The Company's stock went rose 7.36% over the previous three trading sessions, compared to the Dow Jones Industrial Average, which advanced 1.60% during the same trading period. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Keryx Biopharmaceuticals Inc. Research Report
On December 18, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,609,896, which will expire in 2024. According to the Company, the patent claims orally administrable forms of Zerenex prepared from ferric citrate having a BET active surface area greater than about 16 sq. m/g. Keryx informed that the active pharmaceutical ingredient of Zerenex is ferric citrate having a BET surface area substantially above this surface area threshold. Ron Bentsur, CEO of Keryx, commented, "We believe that our portfolio of patents will provide market exclusivity for Zerenex through at least 2024, as the high API surface area Page: 1 2 3 4 5 Related biology technology :1
. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline2
. California Biomedical Companies Report Higher Product Approvals, Fewer Delays3
. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge4
. Synthetic Biologics Announces Proposed Public Offering of Common Stock5
. MiMedx Group Announces Proposed Public Offering of Common Stock6
. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC7
. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants8
. Z Trim Holdings, Inc. Announces Pricing of Public Offering of Common Stock and Warrants9
. DURECT Announces Pricing of Public Offering of Common Stock10
. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock11
. Discovery Labs Prices $50 Million Public Offering of Common Stock
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ... Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... 21 Startech,Environmental Corp. (OTC Bulletin Board: ... Company, announced today that the,EnviroSafe Industrial Services ... its original plans for its new recycling-facility ... to install three Plasma Converters Systems,purchased last ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that it has elected to suspend,enrolment in ... its Vascular Wrap,product candidate in patients undergoing surgery ... an imbalance of infections that have,been observed between ...
... A group of German,investors is about to acquire up ... purchasing price of up to EUR 750,000. The acquisition,will be ... subscribed,to by the investors. It will become effective after the ... and after the capital increase will,have been entered in the ...Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2
(Date:12/11/2014)... , Dec. 10, 2014 Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 9, 2014 Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... 2014 ... Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ... Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...